Switching from selexipag to inhaled treprostinil for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This study tests whether changing from the oral medicine selexipag to an inhaled treatment called treprostinil (LIQ861) can improve symptoms or be better tolerated in adults with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs. If you are currently taking selexipag but it isn't working well enough or causes side effects, this switch might be a good option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with PAH (Group 1) by a heart catheterization test, and it is one of these types: unknown cause, inherited, caused by drugs or toxins, related to connective tissue disease, or linked to a heart defect repaired at least a year ago.
- You have been taking selexipag (any dose between 200 and 1600 mcg twice daily) for at least 90 days, and you are willing to switch to the inhaled treprostinil because the selexipag is not working well enough or causes side effects.
- You may also be taking up to two other approved PAH oral medications, but they must stay at the same dose during the study.
- Your heart function is classified as New York Heart Association (NYHA) Class II or III, meaning you have mild to moderate symptoms.
- You are able to demonstrate correct use of the dry powder inhaler device.
- You do not have certain heart conditions (such as significant left-sided heart disease), have not had symptomatic heart artery disease in the last 6 months, and have not had a prior atrial septostomy (a heart procedure).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how patients feel and how well they stick with their treatment when they switch from an inhaled medicine (iloprost) to a pill (selexipag) for pulmonary arterial hypertension (PAH). It will help doctors understand if the switch improves patient experience.
This trial tests if treprostinil can help people with pulmonary arterial hypertension (PAH) who are at intermediate risk. You may join if you have been diagnosed with certain types of PAH and meet specific heart and lung test results.
This study looks at how well the drug Treprostinil works in people with a specific type of pulmonary hypertension (high blood pressure in the lungs). It helps researchers understand real-world results and side effects.
This study compares two approaches for people with PAH whose current treatment (a combination of sildenafil and an endothelin receptor antagonist) needs to be stepped up. Half the participants will add a third medicine (iloprost or selexipag), while the other half will increase their sildenafil dose. The goal is to see which strategy works better for improving symptoms and lowering risk.
This trial tests whether adding a new drug called tiprelestat to standard pulmonary arterial hypertension (PAH) treatments can help patients breathe better and feel stronger. You'd receive tiprelestat or placebo along with your current PAH medications.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.